All In Biotech

Drug Trial Radar · NCT06551142

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

845

Planned (sponsor's estimate)

Start

Sep 30, 2024

Primary completion

Oct 16, 2028

Study completion Jun 8, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab, tarlatamab, dostarlimab

Conditions

  • Neoplasms

Interventions

  • Ris-RezBiological

    Ris-Rez will be administered

  • CisplatinDrug

    Cisplatin will be administered

  • CarboplatinDrug

    Carboplatin will be administered

  • AtezolizumabBiological

    Atezolizumab will be administered

  • PembrolizumabBiological

    Pembrolizumab will be administered

  • DurvalumabBiological

    Durvalumab will be administered

  • CetuximabBiological

    Cetuximab will be administered

  • BevacizumabBiological

    Bevacizumab will be administered

  • TarlatamabBiological

    Tarlatamab will be administered

  • DostarlimabBiological

    Dostarlimab will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Number of participants with Adverse Events (AEs)Time frame: Up to approximately 28 months
  2. Phase 1a: Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days
  3. Phase 1a: Number of participants with AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs) by severityTime frame: Up to approximately 30 months
  4. Phase 1a: Number of participants with AEs leading to dose modificationsTime frame: Up to approximately 28 months
  5. Phase 1a: Number of participants with changes in vital signs, body weight, laboratory tests, electrocardiogram (ECG) and Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Up to approximately 28 months
  6. Phase 1b: Confirmed Objective Response Rate (cORR)Time frame: Up to approximately 27 months

Locations

67 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Stanford, California · Recruiting

  • GSK Investigational Site

    Denver, Colorado · Recruiting

  • GSK Investigational Site

    New Haven, Connecticut · Recruiting

  • GSK Investigational Site

    Fort Wayne, Indiana · Recruiting

  • GSK Investigational Site

    Boston, Massachusetts · Recruiting

  • GSK Investigational Site

    Detroit, Michigan · Recruiting

  • GSK Investigational Site

    New Brunswick, New Jersey · Recruiting

  • GSK Investigational Site

    Myrtle Beach, South Carolina · Recruiting

  • GSK Investigational Site

    Nashville, Tennessee · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

  • GSK Investigational Site

    Dallas, Texas · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Recruiting

  • GSK Investigational Site

    Tyler, Texas · Recruiting

  • GSK Investigational Site

    West Valley City, Utah · Recruiting

  • GSK Investigational Site

    Norfolk, Virginia · Recruiting

  • GSK Investigational Site

    Rosario, Argentina · Completed

  • GSK Investigational Site

    Viedma, Argentina · Recruiting

  • GSK Investigational Site

    Hamilton, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Ottawa, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Sherbrooke, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Bordeaux, France · Recruiting

  • GSK Investigational Site

    Lyon, France · Recruiting

  • GSK Investigational Site

    Villejuif, France · Recruiting

  • GSK Investigational Site

    Pokfulam, Hong Kong · Recruiting

  • GSK Investigational Site

    Shatin, Hong Kong · Recruiting

  • GSK Investigational Site

    Jerusalem, Israel · Recruiting

  • GSK Investigational Site

    Jerusalem, Israel · Recruiting

  • GSK Investigational Site

    Ramat Gan, Israel · Recruiting

  • GSK Investigational Site

    Tel Aviv, Israel · Recruiting

  • GSK Investigational Site

    Milan, Italy · Recruiting

  • GSK Investigational Site

    Naples, Italy · Recruiting

  • GSK Investigational Site

    Roma, Italy · Recruiting

  • GSK Investigational Site

    Verona, Italy · Recruiting

  • GSK Investigational Site

    Aichi, Japan · Recruiting

  • GSK Investigational Site

    Chiba, Japan · Recruiting

  • GSK Investigational Site

    Shizuoka, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.